posted on 2023-03-30, 12:08authored byDirk Brehmer, Zoltán Greff, Klaus Godl, Stephanie Blencke, Alexander Kurtenbach, Martina Weber, Stefan Müller, Bert Klebl, Matt Cotten, György Kéri, Josef Wissing, Henrik Daub
Supplementary Methods and Figure from Cellular Targets of Gefitinib
History
ARTICLE ABSTRACT
Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.